A Trial of Doxycycline in Renal Disease

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID) will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic kidney disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• CKD pre-dialysis (eGFR< 30 ml/min/1.73m2 not on dialysis);

• local 415/650/510 area codes;

• primary language English or Spanish

Exclusion Criteria:

• eGFR worsening by greater than 5ml/min/1.73 m2 during the last 6 months;

• Systolic blood pressure less than 100mmHg or greater than 170 mmHg;

• pregnancy;

• ejection fraction less than 45%;

• NYHA class III or IV HF;

• myocardial infarction or hospitalization for HF within 4 months;

• liver disease;

• moderate or severe chronic obstructive pulmonary disease or pulmonary fibrosis;

• current infection;

• chemotherapy;

• major surgery within last month;

• bilateral dialysis access precluding lab draw;

• self-reported use of IV drugs or cocaine within the last 6 months.